Pfizer’s Ibrance ‘unlikely’ to hit key early breast cancer goal
The trial is unlikely to show a statistically significant improvement in invasive disease-free survival
Read More
Tag: PALLAS
- Myomaker Bio unveils lab‑grown human muscle platform to transform drug testing
- Survodutide delivers 16.6% weight loss in major phase 3 obesity trial
- Kahimmune Therapeutics signs collaboration agreement with Gustave Roussy
- BioDuro and CTI Biotechnology form partnership to accelerate preclinical drug development
- Asgard Therapeutics to present new preclinical data on AT‑108 at ASGCT 2026
